Daniel Lasanow
Chairman presso Polypeptide Laboratories France SAS
Patrimonio netto: 261 286 $ in data 31/03/2024
Profilo
Daniel Lasanow currently works at Polypeptide Laboratories France SAS, as Chairman from 2017.
Mr. Lasanow also formerly worked at Lonza, Inc., as Production Director, NextPharma Technologies SA (Belgium), as Production Director from 2009 to 2011, UCB-Bioproducts SA, as Production Director, and PolyPeptide Group AG, as Director-Global Operations from 2016 to 2022.
Mr. Lasanow received his graduate degree from Université Catholique de Louvain.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
POLYPEPTIDE GROUP AG
0.02% | 31/12/2022 | 7 767 ( 0.02% ) | 261 286 $ | 31/03/2024 |
Posizioni attive di Daniel Lasanow
Società | Posizione | Inizio |
---|---|---|
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Chairman | 10/04/2017 |
Precedenti posizioni note di Daniel Lasanow
Società | Posizione | Fine |
---|---|---|
POLYPEPTIDE GROUP AG | Chief Operating Officer | 30/11/2022 |
NextPharma Technologies SA (Belgium) | Corporate Officer/Principal | 01/01/2011 |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Corporate Officer/Principal | - |
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Corporate Officer/Principal | - |
Formazione di Daniel Lasanow
Université Catholique de Louvain | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
POLYPEPTIDE GROUP AG | Health Technology |
Aziende private | 4 |
---|---|
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Process Industries |
NextPharma Technologies SA (Belgium) | |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Commercial Services |
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Process Industries |
- Borsa valori
- Insiders
- Daniel Lasanow